Literature DB >> 33299828

The benefit of curative liver resection with a selective bile duct preserving approach for hepatocellular carcinoma with macroscopic bile duct tumor thrombus.

Anon Chotirosniramit1, Akkaphod Liwattanakun1, Sunhawit Junrungsee1, Wasana Ko-Iam1, Trichak Sandhu1, Worakitti Lapisatepun1.   

Abstract

BACKGROUND: Hepatocellular carcinoma (HCC) presenting with macroscopic bile duct tumor thrombus (BDTT) is an uncommon event. The role of a curative hepatic resection and associated long-term outcomes remain controversial. In addition the necessity for bile duct resection is still unclear. The aim of this study was to evaluate outcomes of hepatectomy with a selective bile duct preservation approach for HCC with BDTT in comparison to outcomes without BDTT.
METHODS: A total of 22 HCC with BDTT patients who had undergone curative hepatic resection with a selective bile duct preservation approach at our institute were retrospectively reviewed. These were compared to group of 145 HCC without BDTT patients. The impact of curative surgical resection and BDTT on clinical outcomes and survival after surgical resection were analyzed.
RESULTS: All HCC with BDTT cases underwent major hepatectomy vs. 32.4% in the comparative group. Bile duct preservation rate was 56.5%. The 1-, 3- and 5-year survival rates of HCC with BDTT patients in comparison to the HCC without BDTT group were 81.8%, 52.8% and 52.8% vs. 73.6%, 55.6% and 40.7% (P=0.804) respectively. Positive resection margin, tumor size ≥5 cm and AFP ≥200 IU/mL were significant risk factors regarding overall survival. However, it is unclear whether presence of a bile duct tumor thrombus has an adverse impact on either recurrence free survival or overall survival.
CONCLUSIONS: Bile duct obstruction from tumor thrombus did not necessarily indicate an advanced form of disease. Tumor size and AFP had greater impact on long-term outcomes than bile duct tumor thrombus. Major liver resection with a selective bile duct preserving approach in HCC with BDTT can achieve favorable outcomes comparable to those of HCC without BDTT in selected patients. 2020 Hepatobiliary Surgery and Nutrition. All rights reserved.

Entities:  

Keywords:  Hepatocellular carcinoma (HCC); bile duct preserve; bile duct tumor thrombus (BDTT); outcomes

Year:  2020        PMID: 33299828      PMCID: PMC7720058          DOI: 10.21037/hbsn.2019.10.26

Source DB:  PubMed          Journal:  Hepatobiliary Surg Nutr        ISSN: 2304-3881            Impact factor:   7.293


  23 in total

1.  Hepatitis B virus genotypes and hepatocellular carcinoma in Thailand.

Authors:  Pisit Tangkijvanich; Varocha Mahachai; Piyawat Komolmit; Juthatip Fongsarun; Apiradee Theamboonlers; Yong Poovorawan
Journal:  World J Gastroenterol       Date:  2005-04-21       Impact factor: 5.742

2.  Hepatocellular carcinoma (HCC): a global perspective.

Authors:  Peter Ferenci; Michael Fried; Douglas Labrecque; Jordi Bruix; Morris Sherman; Masao Omata; Jenny Heathcote; Teehra Piratsivuth; Mike Kew; Jesse A Otegbayo; S S Zheng; S Sarin; Saeed S Hamid; Salma Barakat Modawi; Wolfgang Fleig; Suliman Fedail; Alan Thomson; Aamir Khan; Peter Malfertheiner; George Lau; Flair J Carillo; Justus Krabshuis; Anton Le Mair
Journal:  J Clin Gastroenterol       Date:  2010-04       Impact factor: 3.062

3.  Bile duct preserving surgery for hepatocellular carcinoma with bile duct tumor thrombus.

Authors:  Satoshi Yamamoto; Kiyoshi Hasegawa; Yousuke Inoue; Junichi Shindoh; Taku Aoki; Yoshihiro Sakamoto; Yasuhiko Sugawara; Masatoshi Makuuchi; Norihiro Kokudo
Journal:  Ann Surg       Date:  2015-05       Impact factor: 12.969

4.  Classification and surgical treatment of hepatocellular carcinoma (HCC) with bile duct thrombi.

Authors:  M Ueda; T Takeuchi; T Takayasu; K Takahashi; S Okamoto; A Tanaka; T Morimoto; K Mori; Y Yamaoka
Journal:  Hepatogastroenterology       Date:  1994-08

5.  Outcomes of hepatectomy for hepatocellular carcinoma with bile duct tumour thrombus.

Authors:  Tiffany C L Wong; Tan To Cheung; Kenneth S H Chok; Albert C Y Chan; Wing Chiu Dai; See Ching Chan; Ronnie T P Poon; Sheung Tat Fan; Chung Mau Lo
Journal:  HPB (Oxford)       Date:  2014-11-19       Impact factor: 3.647

6.  Intrahepatic bile duct recurrence of hepatocellular carcinoma without a detectable liver tumor.

Authors:  Tomoyuki Abe; Kiyoshi Kajiyama; Norifumi Harimoto; Tomonobu Gion; Ken Shirabe; Takashi Nagaie
Journal:  Int J Surg Case Rep       Date:  2012-03-28

7.  Surgical intervention for obstructive jaundice due to biliary tumor thrombus in hepatocellular carcinoma.

Authors:  Shu You Peng; Jian Wei Wang; Ying Bin Liu; Xiu Jun Cai; Gui Long Deng; Bin Xu; Hai Jun Li
Journal:  World J Surg       Date:  2003-11-26       Impact factor: 3.352

8.  Surgical outcomes of hepatocellular carcinoma with bile duct tumor thrombus: a Korean multicenter study.

Authors:  Deok-Bog Moon; Shin Hwang; Hee-Jung Wang; Sung-Su Yun; Kyung Sik Kim; Young-Joo Lee; Ki-Hun Kim; Yong-Keun Park; Weiguang Xu; Bong-Wan Kim; Dong Shik Lee; Dong-Hyun Lee; Hong-Jin Kim; Jin Hong Lim; Jin Sub Choi; Yo-Han Park; Sung-Gyu Lee
Journal:  World J Surg       Date:  2013-02       Impact factor: 3.352

9.  Prognosis of hepatocellular carcinoma patients with bile duct tumor thrombus after hepatic resection or liver transplantation in Asian populations: A meta-analysis.

Authors:  Chenglin Wang; Yu Yang; Donglin Sun; Yong Jiang
Journal:  PLoS One       Date:  2017-05-04       Impact factor: 3.240

10.  A single institution report of 19 hepatocellular carcinoma patients with bile duct tumor thrombus.

Authors:  Anon Chotirosniramit; Akkaphod Liwattanakun; Worakitti Lapisatepun; Wasana Ko-Iam; Trichak Sandhu; Sunhawit Junrungsee
Journal:  J Hepatocell Carcinoma       Date:  2017-03-07
View more
  1 in total

1.  Redefining Hepatocellular Carcinoma Staging Systems Based on the Bile Duct Invasion Status: A Multicenter Study.

Authors:  Qizhen Huang; Yufeng Chen; Kongying Lin; Chuandong Sun; Shuguo Zheng; Jinhong Chen; Yifan Wang; Yanming Zhou; Weiping Zhou; Jingfeng Liu; Yongyi Zeng
Journal:  Front Oncol       Date:  2021-10-14       Impact factor: 6.244

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.